Literature DB >> 24376295

Warthin's tumour of the parotid gland: our experience.

T C Chulam1, A L Noronha Francisco2, J Goncalves Filho1, C A Pinto Alves3, L P Kowalski1.   

Abstract

Benign tumours account for approximately 60-80% of parotid neoplasms and among these, Warthin's tumour is the second most common benign neoplasm accounting for approximately 15% of all parotid epithelial tumours. The medical records of 100 consecutive patients with Warthin's tumour of the parotid gland admitted for treatment at the Department of Head and Neck Surgery and Otorhinolaryngology, Hospital A.C. Camargo, São Paulo, Brazil, between 1983 and 2011 were retrospectively analyzed. The surgical procedures included 104 (96%) subtotal parotidectomies and 4 (3.7%) total parotidectomies. One hundred and eight parotidectomies were performed in 100 patients with Warthin's tumour. Postoperative complications occurred in 67 (62.3%) of surgical procedures, and facial nerve dysfunction was the most frequent complication, occurring in 51 of 108 surgeries (47.2%). The marginal mandibular branch of the facial nerve was affected in 46 of the 48 cases (95.8%) of facial nerve dysfunction. Frey's syndrome was diagnosed in the late postoperative period in 19 patients (17.6%). We conclude that either superficial or total parotidectomy with preservation of facial nerve are the treatment of choice for Warthin's tumour with no case of recurrence seen after long-term follow-up. Facial nerve dysfunction and Frey's syndrome were the main complications associated with this surgery. Thus, if on one hand total parotidectomy is an appropriate radical resection of parotid parenchyma reducing, in theory, the risk of recurrence, on the other hand superficial parotidectomy is also a radical and efficient method with lower morbidity in terms of facial nerve dysfunction and Frey's syndrome.

Entities:  

Keywords:  Complications; Parotid; Parotid tumours; Recurrence; Treatment; Warthin's tumour

Mesh:

Year:  2013        PMID: 24376295      PMCID: PMC3870448     

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


Introduction

Benign tumours account for approximately 60-80% of parotid neoplasms and comprise a heterogeneous group with distinct clinical and histological features and biological behaviour . Among these, Warthin's tumour, also known as adenolymphoma or papillary lymphomatous cystadenoma, is the second most common benign neoplasm and accounts for approximately 15% of parotid epithelial tumours -. Warthin's tumour is most common in male patients (4:1 male:female ratio) during the sixth and seventh decades of life . Unlike other benign neoplasms of the salivary glands, this tumour has a tendency towards bilateral involvement, and approximately 90% of lesions occur in the superficial lobe of the parotid gland . Histologically, the tumour has an oncocytic epithelial component forming uniform rows of cells surrounded by cystic spaces associated with a lymphoid stroma often showing the presence of germinal centres (Figs. 1, 2) . Treatment consists of partial, subtotal or total parotidectomy with preservation of the facial nerve . Malignant transformation is described in only 0.1% of cases, and usually arises in the epithelial component of the lymphoid tissue tumour . The incidence of recurrence after surgical treatment is extremely rare .
Fig. 1.

Histological section stained with HE with 40x magnification, showing the interface between the salivary gland and the tumor.

Fig. 2.

Histological section stained with HE with 40x magnification, demonstrating the neoplasm characterized by cystic and solid areas, cells with abundant granular and eosinophilic cytoplasm with central nuclei. The stroma is rich in lymphocytes.

Histological section stained with HE with 40x magnification, showing the interface between the salivary gland and the tumor. Histological section stained with HE with 40x magnification, demonstrating the neoplasm characterized by cystic and solid areas, cells with abundant granular and eosinophilic cytoplasm with central nuclei. The stroma is rich in lymphocytes. The aim of this study is to describe the outcomes of patients with Warthin's tumour of the parotid gland considering clinical and demographic characteristics, type of surgery, complications and the incidence of recurrence.

Patients and methods

The medical records of 100 consecutive patients with Warthin's tumour of the parotid gland admitted for treatment at the Department of Head and Neck Surgery and Otorhinolaryngology, Hospital "A.C. Camargo", São Paulo, Brazil, between 1983 and 2011 were retrospectively analyzed. One hundred and thirteen tumours were diagnosed in 100 patients with a median age of 58 years (range 32-84 years). There were 72 males and 28 females. Of these, 75 patients (75%) were Caucasian. Tobacco use was reported at diagnosis by 72 patients and 11 reported a previous history of smoking. Four patients had bilateral synchronous tumours and 9 had bilateral metachronous tumours. The treatment employed was surgery in all cases. The surgeries were performed by several surgeons from the same department, mostly residents directly supervised by specialists in head and neck surgery. The surgical procedures included 104 (96%) subtotal/superficial parotidectomies, defined by the resection of tumours located in the superficial portion of the gland (above the nerve) and 4 (3.7%) total parotidectomies, indicated for those tumours located in the deep lobe of gland. The facial nerve was identified and preserved in all cases. In three of the four patients with bilateral synchronous tumours, surgery was performed only on the side where the tumour was larger. Otherwise, in 9 patients with metachronous bilateral tumours, contralateral parotidectomy was performed in 7 cases. All eight contralateral parotidectiomies in patients with bilateral tumours were performed at different times. In five patients with bilateral tumours, the second side was not operated because of patient refusal or for clinical reasons (small tumours and few symptoms). Routinely, the facial nerve trunk is identified before making the identification and dissection of its branches. No devices were used to identify the nerve in primary surgeries. In two patients, the mandibular branch of facial nerve was sacrificed because of reported tumour involvement, and these cases were not included in the analysis of postoperative nerve dysfunction. Rotation of sternocleidomastoid muscle flap (SMF) was performed in the last 10 years to fill the parotid bed after resection and to reduce the incidence of Frey's syndrome. The type of drain used varied during the study period. The Penrose drains that were originally used were replaced in 1994 by vacuum drainage Hemovac (Portovac), and in the last decade we have used silicone drains (Jackson-Pratt and Blake) to facilitate postoperative care and allow early hospital discharge. SPSS 17.0 was used for statistical analysis. The association between variables with the occurrence of complications was evaluated by chi-square or Fisher's exact test, as appropriate. The Mann-Whitney test was used to evaluate the difference between the mean length of hospitalization. A p value < 0.05 was considered statistically significant.

Results

One hundred and eight parotidectomies were performed in 100 patients with Warthin's tumour. The time of hospitalization varied from 1 to 19 days (median, 2 days). Postoperative complications occurred in 67 (62.3%) surgical procedures, and facial nerve dysfunction was the most frequent complication, followed by other less frequent complications such as seroma and infection (Table I). There was no total facial nerve dysfunction or postoperative mortality. The mean and median days of hospitalization between the patients who did or did not have postoperative complications were similar and not statistically different. Similarly, the incidence of postoperative complications did not show statistically significant correlation with gender, age, smoking and alcohol, type of parotidectomy, nodule size and use of the sternocleidomastoid muscle flap.
Table I.

Complications in 108 parotidectomies for Warthin's tumour.

Complicationn%
Number*4440.7
Facial nerve dysfunction5147.2
Infection109.2
Seroma20.9
Haematoma20.9
Fistula20.9

Some patients had more than one complication.

Complications in 108 parotidectomies for Warthin's tumour. Some patients had more than one complication. Postoperative facial nerve dysfunction occurred in 51 of 108 surgeries (47.2%) (Table I). In 43 cases (84.3%), dysfunction was transitory with recovery of function occurring in a period ranging from 1 to 19 months (median, 4 months). Unfortunately, in eight cases there was no detailed report in the clinical chart regarding recovery from facial mobility. The marginal mandibular branch of the facial nerve was affected in 46 of the 49 cases (93.8%). Six cases (12.2%) had dysfunction of other associated branches. Only one patient had postoperative dysfunction of all branches of the facial nerve. Seroma and haematoma were found in 2 of 108 (1.9%) procedures. All were treated conservatively with aspiration. Wound infection was observed in 10 of 108 (9.2%) procedures. There was no statistically significant correlation with the incidence of wound infection and the type of drain used. Two cases of fistula occurred. Frey's syndrome was diagnosed in the late postoperative period in 19 patients (17.6%) (Table II). There were no reports of bilateral Frey's syndrome in patients with surgery on both sides. Frey's syndrome occurred less frequently in patients who underwent rotation of the sternocleidomastoid muscle flap (SMF) to fill the parotidectomy field (10 of 67; 14.9%) compared with cases that did not undergo flap reconstruction (9 of 41; 22%), but this difference was not statistically significant.
Table II.

Incidence of Frey's Syndrome.

Frey's Syndrome
NoYes
ParotidectomyPartial7819
Total40
SMFNo219
Yes5910
Follow-upMin6 m
Max20 y
Mean4.13 y
Median2 y

SMF: sternocleidomastoid muscle flap; m: month; y: years.

Incidence of Frey's Syndrome. SMF: sternocleidomastoid muscle flap; m: month; y: years.

Discussion

Warthin's tumour is a benign neoplasm, first described by Aldred Warthin in 1929, which occurs predominantly in the parotid gland and represents approximately 15% of parotid tumours . Fewer than 10% of cases occur outside this gland . Furthermore, bilateralism is described in 5-15% of cases and multifocality in 6-20% -. In our series, we studied only tumours of the parotid gland, and bilateral Warthin's tumours were observed in 13 (13%) patients, (4 synchronous cases and 9 metachronous cases). Although the occurrence of bilateral Warthin's tumour is relatively common in this group of patients, the presence of a bilateral synchronic tumour is rare -. The origin of Warthin's tumour is unknown and its classification as cancer is controversal . Surgery is the main mode of therapy used and is associated with a low recurrence rate . Several authors have correlated recurrence rate with the extent of surgery, which ranges from 0-13% . In our study, superficial parotidectomy with facial nerve preservation was used in 97% of cases, and there were no cases of recurrence after a median followup of 31 months. Although superficial parotidectomy is the treatment of choice for patients with benign tumours of the parotid gland, it is associated with both early and late complications . The main complications associated with surgery of the parotid gland are facial nerve dysfunction and Frey's syndrome. Postoperative dysfunction of the facial nerve may be total or partial (some branches), and transient or permanent . On the other hand, Frey's syndrome is detected later, may be symptomatic or asymptomatic and its diagnosis is performed with the Minor test that is based on application of a solution containing 1.5 g of iodine, 10 g of castor oil and 88.5 g of absolute alcohol that must be applied to the skin of the parotid region. After drying, starch powder should be applied, which together with local sweating, will produce a blue iodine-starch reaction . In the literature, the incidence of transient dysfunction of the facial nerve has been reported in 10-68% of cases, while permanent dysfunction occurs in 0-19% . In our series, the incidence of postoperative dysfunction of facial nerve was 47.2%. The marginal mandibular branch was the most affected with 90% of cases of nerve dysfunction, although total dysfunction (all branches) was detected in only 1 patient. Classification regarding the degree of facial nerve dysfunction could not be done since this was a retrospective study, and this data was not evaluated in most cases. Dysfunction of the marginal mandibular branch is a major problem and has been reported in 48-59% of cases in the literature . Several factors have been described to be associated with an increased incidence of postoperative dysfunction of the facial nerve after parotidectomy . Yuan, in 2009, studied 626 patients undergoing surgery for benign disease of the parotid and found that the factors associated with increased postoperative dysfunction of the facial nerve were the extent of parotidectomy and diabetes mellitus . Similarly, Koch in 2010 observed facial nerve dysfunction in 32.7% of cases, and the main factor was the extent of surgery . In another study of 162 patients who underwent parotidectomy for benign disease, the presence of facial nerve dysfunction was observed in 40% of cases. In this study, the presence of inflammation and parotidectomy for Warthin's tumour were the factors that were most relevant to dysfunction . In our study, there were no factors that significantly correlated with postoperative dysfunction of the facial nerve. Frey's syndrome has been described as a main complication related to surgery of the parotid gland. The incidence of this syndrome varies widely according to the diagnostic investigation. It is reported spontaneously for about 10% of patients, but when questioned actively about the existence of gustatory sweating, approximately 30-40% of patients report the presence of such symptoms. Moreover, when under diagnostic investigation, Frey's syndrome is seen in up to 95% of patients undergoing parotidectomy . In our study, the diagnosis of Frey's syndrome was made based on spontaneously clinical complaints of the patient or after being questioned by the attending physician about symptoms during follow-up, and was seen in 17.6% of patients. This occurred more often in patients in whom a SMF was not used to fill the parotid space (22% vs. 14.9%). However, this difference was not statistically significant. When symptomatic, Frey's syndrome was treated with botulinum toxin injection in the most severe cases, and by applying deodorants or antiperspirants in milder cases. Queiroz Filho, in 2004, studied the occurrence of Frey's syndrome in 2 groups of patients according to the presence or absence of SMF and found that 47.4% (9/19) of patients in the group who did not receive the flap had complaints of gustatory sweating, and in 36.8% (7/12) of patients the Minor test was positive. Otherwise, in the group that received the flap, complaints or a positive test for Minor were not found . In a systematic literature review, Sanabria concluded that there is not sufficient clinical evidence to determine that the use of SMF in preventing Frey's syndrome is an effective procedure in preventing Frey's syndrome . We conclude that either superficial or total parotidectomy with preservation of the facial nerve are the preferred treatments for Warthin's tumour with no case of tumour recurrence seen during long-term follow-up. Facial nerve dysfunction and Frey's syndrome were the main complications associated with this surgery. Thus, if in one hand, total parotidectomy is an appropriate radical resection of parotid parenchyma reducing, in theory, the risk of recurrence, on the other superficial parotidectomy is also a radical and efficient method with low morbidity in terms of facial nerve dysfunction and Frey's syndrome. Currently, resections such as those of the lower extremity of the superficial pole of parotid should not be ruled out, as they can be performed safely in lower tumours, allowing lower manipulation of cranial branches of the facial nerve with less morbidity. However, further prospective and randomized studies are needed to reach a more definitive conclusion.
  26 in total

1.  Molecular assessment of allelic loss in Warthin tumors.

Authors:  Muammar Arida; E Leon Barnes; Jennifer L Hunt
Journal:  Mod Pathol       Date:  2005-07       Impact factor: 7.842

2.  Parotidectomy: ten-year review of 237 cases at a single institution.

Authors:  David C Upton; Justin P McNamar; Nadine P Connor; Paul M Harari; Gregory K Hartig
Journal:  Otolaryngol Head Neck Surg       Date:  2007-05       Impact factor: 3.497

3.  Facial nerve dysfunction after parotidectomy: the role of local factors.

Authors:  Christophe Gaillard; Sophie Périé; Bertrand Susini; Jean Lacau St Guily
Journal:  Laryngoscope       Date:  2005-02       Impact factor: 3.325

4.  Risk of facial palsy and severe Frey's syndrome after conservative parotidectomy for benign disease: analysis of 610 operations.

Authors:  Orlando Guntinas-Lichius; Bettina Gabriel; J Peter Klussmann
Journal:  Acta Otolaryngol       Date:  2006-10       Impact factor: 1.494

5.  Facial nerve function after parotidectomy.

Authors:  L P Bron; C J O'Brien
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1997-10

Review 6.  Management of Frey syndrome.

Authors:  Remco de Bree; Isaäc van der Waal; C René Leemans
Journal:  Head Neck       Date:  2007-08       Impact factor: 3.147

Review 7.  Warthin's tumor: a 40-year experience at The Johns Hopkins Hospital.

Authors:  G H Yoo; D W Eisele; F B Askin; J S Driben; M E Johns
Journal:  Laryngoscope       Date:  1994-07       Impact factor: 3.325

8.  Clinical features of cystadenolymphoma (Warthin's tumor) of the parotid gland: a retrospective comparative study of 96 cases.

Authors:  A Teymoortash; Y Krasnewicz; J A Werner
Journal:  Oral Oncol       Date:  2006-02-15       Impact factor: 5.337

Review 9.  [Bilateral adenolymphoma (Warthin's tumor) of the parotid. The anatomicoclinical, diagnostic and therapeutic aspects of 2 cases].

Authors:  G F Favia; D Pratelli; M Bux; V De Falco
Journal:  Minerva Stomatol       Date:  1994-11

10.  Sternocleidomastoid muscle flap preventing Frey syndrome following parotidectomy.

Authors:  Wail Queiroz Filho; Rogério A Dedivitis; Abrão Rapoport; André V Guimarães
Journal:  World J Surg       Date:  2004-03-17       Impact factor: 3.352

View more
  12 in total

1.  Warthin tumor within the superficial lobe of the parotid gland: a suggested criterion for diagnosis.

Authors:  Doron Sagiv; Robert L Witt; Eran Glikson; Jobran Mansour; Bruria Shalmon; Arkadi Yakirevitch; Michael Wolf; Eran E Alon; Guy Slonimsky; Yoav P Talmi
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-24       Impact factor: 2.503

2.  The role of fine-needle aspiration biopsy (FNAB) in Warthin tumour diagnosis and management.

Authors:  Alzbeta Jechova; Martin Kuchar; Stepan Novak; Vladimir Koucky; Lucie Dostalova; Michal Zabrodsky; David Kalfert; Jan Plzak
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-18       Impact factor: 2.503

3.  Increased incidence of Warthin tumours of the parotid gland: a 42-year evaluation.

Authors:  Achim M Franzen; Christiane Kaup Franzen; Thomas Guenzel; Anja Lieder
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-18       Impact factor: 2.503

4.  Apparent Diffusion Coefficient Map-Based Radiomics Features for Differential Diagnosis of Pleomorphic Adenomas and Warthin Tumors From Malignant Tumors.

Authors:  Baohong Wen; Zanxia Zhang; Jing Zhu; Liang Liu; Yinhua Li; Haoyu Huang; Yong Zhang; Jingliang Cheng
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

Review 5.  Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland.

Authors:  Miquel Quer; Juan C Hernandez-Prera; Carl E Silver; Maria Casasayas; Ricard Simo; Vincent Vander Poorten; Orlando Guntinas-Lichius; Patrick J Bradley; Wai Tong-Ng; Juan P Rodrigo; Antti A Mäkitie; Alessandra Rinaldo; Luiz P Kowalski; Alvaro Sanabria; Remco de Bree; Robert P Takes; Fernando López; Kerry D Olsen; Ashok R Shaha; Alfio Ferlito
Journal:  Diagnostics (Basel)       Date:  2021-08-13

Review 6.  Use of the SMAS flap for reconstruction of the parotid lodge.

Authors:  G Dell'Aversana Orabona; G Salzano; V Abbate; P Piombino; F Astarita; G Iaconetta; L Califano
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-12       Impact factor: 2.124

7.  Oxidative Stress Markers Patients with Parotid Gland Tumors: A Pilot Study.

Authors:  Pawel Sowa; Maciej Misiolek; Bartlomiej Pasinski; Grzegorz Bartosz; Miroslaw Soszynski; Monika Adamczyk-Sowa; Izabela Sadowska-Bartosz
Journal:  Biomed Res Int       Date:  2018-01-30       Impact factor: 3.411

8.  Expressions of CXCL12, CXCL10 and CCL18 in Warthin tumors characterized pathologically by having a lymphoid stroma with germinal centers.

Authors:  Kunio Mochizuki; Naoki Oishi; Masataka Kawai; Toru Odate; Ippei Tahara; Tomohiro Inoue; Kazunari Kasai; Tetsuo Kondo
Journal:  Histol Histopathol       Date:  2021-06-14       Impact factor: 2.303

9.  Differential diagnosis of parotid gland tumours: which magnetic resonance findings should be taken in account?

Authors:  T Tartaglione; A Botto; M Sciandra; S Gaudino; L Danieli; C Parrilla; G Paludetti; C Colosimo
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-10       Impact factor: 2.124

10.  Improving the diagnosis of common parotid tumors via the combination of CT image biomarkers and clinical parameters.

Authors:  Dan Zhang; Xiaojiao Li; Liang Lv; Jiayi Yu; Chao Yang; Hua Xiong; Ruikun Liao; Bi Zhou; Xianlong Huang; Xiaoshuang Liu; Zhuoyue Tang
Journal:  BMC Med Imaging       Date:  2020-04-15       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.